Compare BIO-TECHNE Corp (TECH) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Xcel Energy Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Xcel Energy Inc trades at $77.47 (market cap $48.02B). The key difference: Xcel Energy Inc is far larger — about 4.3× BIO-TECHNE Corp's market cap, and Xcel Energy Inc pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| TECH | XEL | |
|---|---|---|
Market Cap | $11.24B | $48.02B |
Sector | Health | Utilities |
52-Week High | $72.29 | $83.91 |
52-Week Low | $43.31 | $71.75 |
Enterprise Value | $11.32B | $86.33B |
Dividend Yield | 0.44% | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Xcel Energy (XEL) trades at $78.07, up 1.43% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67B with a net income margin of 15.28%, while the balance sheet shows rising assets and liabilities, with a debt-to-asset ratio of 41.57% in 2024. Recent news highlights community investment and board additions.
The outlook for XEL is supported by a $60 billion capital plan targeting 11% annual rate base growth, but regulatory pushback and affordability concerns pose risks. Analyst consensus is bullish with a $93.80 price target, implying 20% upside, though technical indicators suggest near-term caution. Earnings growth and utility demand trends remain key catalysts for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
